Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Diversifying its portfolio to include late-phase antiviral agent
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated